Acyclic Acid Or Salt Thereof Patents (Class 514/578)
  • Patent number: 10322100
    Abstract: This invention teaches the use of chelating agents to diagnose and treat metal toxins in a patient. Chelation agents are given to the mother for the benefit of the baby. Metal toxins such as lead, arsenic, mercury, tin, antimony, aluminum and others are known to cause miscarriages, birth defects, maldevelopment of the organs and tissues and maldevelopment of the brain. Chelation treatments of the mother can prevent these problems in the embryo, fetus and infant. Removal of lead and mercury and other toxins allows improved development of the offspring, both during the chelation and after the chelation is discontinued. Determining whether a mother who has just delivered a baby has elevated levels of heavy metals can also be used to identify the elevated metals of the mother as a possible cause of birth defects.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: June 18, 2019
    Inventor: Patrick James Baggot
  • Patent number: 9975848
    Abstract: The disclosure provides compositions and methods for sensitizing primary HIV-1, including transmitted/founder viruses, to neutralization by monoclonal antibodies, e.g., those directed against CD4-induced (CD4i) epitopes and the V3 region. In certain embodiments, the disclosure relates to the use of small molecules as microbicides to inhibit HIV-1 infection directly and to sensitize primary HIV-1 to neutralization by readily elicited antibodies.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: May 22, 2018
    Assignees: The Trustees of the University of Pennsylvania, Dana-Farber Cancer Institute, Inc., Bryn Mawr College
    Inventors: Amos B. Smith, III, Joseph Sodroski, Navid Madani, Bruno Melillo, Judith M. LaLonde, Amy M. Princiotto
  • Patent number: 9889113
    Abstract: The present invention provides methods of treating soft tissue calcification in a subject, comprising a step of administering to said subject an effective amount of ferric organic compound, such as ferric citrate. The claimed methods may prevent, reverse, delay or stabilize soft tissue calcification in a subject having chronic kidney disease. Affected soft tissue calcification includes soft tissue calcification in the joint, skin, eye, in cardiovascular system such as heart valve, myocardium, coronary arteries and arteriole, or in internal organs such as kidney and lung.
    Type: Grant
    Filed: September 4, 2017
    Date of Patent: February 13, 2018
    Assignee: Panion & BF Biotech Inc.
    Inventors: Keith Chan, Winston Town, Shou Shan Chiang
  • Patent number: 9750715
    Abstract: The present invention provides methods of treating soft tissue calcification in a subject, comprising a step of administering to said subject an effective amount of ferric organic compound, such as ferric citrate. The claimed methods may prevent, reverse, delay or stabilize soft tissue calcification in a subject having chronic kidney disease. Affected soft tissue calcification includes soft tissue calcification in the joint, skin, eye, in cardiovascular system such as heart valve, myocardium, coronary arteries and arteriole, or in internal organs such as kidney and lung.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: September 5, 2017
    Assignee: Panion & Biotech Inc.
    Inventors: Keith Chan, Winston Town, Shou Shan Chiang
  • Patent number: 9700533
    Abstract: This invention teaches the use of chelating agents to diagnose and treat metal toxins in a patient. Chelation agents are given to the mother for the benefit of the baby. Metal toxins such as lead, arsenic, mercury, tin, antimony, aluminum and others are known to cause miscarriages, birth defects, maldevelopment of the organs and tissues and maldevelopment of the brain. Chelation treatments of the mother can prevent these problems in the embryo, fetus and infant. Removal of lead and mercury and other toxins allows improved development of the offspring, both during the chelation and after the chelation is discontinued. Determining whether a mother who has just delivered a baby has elevated levels of heavy metals can also be used to identify the elevated metals of the mother as a possible cause of birth defects.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: July 11, 2017
    Inventor: Patrick James Baggot
  • Patent number: 9468612
    Abstract: Fibrotic diseases are characterized by the replacement of healthy tissue with scar tissue and extracellular matrix in response to tissue damage. Here we describe the reduction of extracellular matrix (ECM) deposition, interstitial fibroblasts, interstitial volume, expression of Collagen I mRNA and protein, expression of profibrotic cytokines and macrophage infiltration by Cysteamine treatment.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: October 18, 2016
    Assignee: Seattle Children's Hospital
    Inventors: Allison A. Eddy, Daryl M. Okamura
  • Patent number: 9421220
    Abstract: Biologically acceptable composition for the prophylaxis and/or treatment of colorectal cancer. The composition contains an iron chelator, and the composition is adapted for the selective targeting of the iron chelator to the colon. The iron chelator is non-digestible, non-absorbable and non-fermentable in the gastrointestinal tract.
    Type: Grant
    Filed: October 26, 2010
    Date of Patent: August 23, 2016
    Assignee: THE UNIVERSITY OF BIRMINGHAM EDGBASTON
    Inventors: Chris Tselepis, Tariq Iqbal, Owen James Sansom
  • Patent number: 9403763
    Abstract: Described herein are small-molecule mimics of CD4, which both enter the Phe43 cavity and target Asp368 of gp120, the HIV-1 envelope protein. Also described herein are methods of using these compounds to inhibit the transmission or progression of HIV infection. These compounds exhibit antiviral potency greater than that of a known antiviral, NBD-556, with 100% breadth against clade B and C viruses. Importantly, the compounds do not activate HIV infection of CD4-negative, CCR5-positive cells, in contrast to NBD-556.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: August 2, 2016
    Inventors: Joseph Sodroski, Judith M. LaLonde, Amos B. Smith, III, Peter D. Kwong, Young Do Kwon, David M. Jones, Alexander W. Sun, Joel R. Courter, Takahiro Soeta, Toyoharu Kobayashi, Amy M. Princiotto, Xueling Wu, John R. Mascola, Arne Schon, Ernesto Freire, Navid Madani, Matthew Le-Khac, Wayne A. Hendrickson, Jongwoo Park
  • Patent number: 9186376
    Abstract: This invention teaches the use of chelating agents to diagnose and treat metal toxins in a patient. Chelation agents are given to the mother for the benefit of the baby. Metal toxins such as lead, arsenic, mercury, tin, antimony, aluminum and others are known to cause miscarriages, birth defects, maldevelopment of the organs and tissues and maldevelopment of the brain. Chelation treatments of the mother can prevent these problems in the embryo, fetus and infant. Removal of lead and mercury and other toxins allows improved development of the offspring, both during the chelation and alter the chelation is discontinued. Determining whether a mother who has just delivered a baby has elevated levels of heavy metals can also be used to identify the elevated metals of the mother as a possible cause of birth defects.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: November 17, 2015
    Inventor: Patrick James Baggot
  • Patent number: 9029419
    Abstract: The subject matter of the present invention is Zn N-acetyltaurinate of formula: [CH3—CO—NH—CH2—CH2—SO3]2?Zn2+ for preventing and/or treating diseases with lipofuscin accumulation due in particular to aging or to oxidative stress, and for preparing a medicament that is of use in treating these diseases. Use: treatment of diseases related to aging or to oxidative stress, in particular age-related macular degeneration and diabetic retinopathy.
    Type: Grant
    Filed: February 25, 2009
    Date of Patent: May 12, 2015
    Assignee: TRI-INOV
    Inventor: Jean Durlach
  • Publication number: 20150119383
    Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.
    Type: Application
    Filed: June 5, 2014
    Publication date: April 30, 2015
    Inventors: Barry S. Fogel, William D. Kerns, Kei-Lai Fong, San-Laung Chow, Edward Lin, David Wong
  • Patent number: 8999400
    Abstract: An aqueous disinfecting solution having a pH of from about 0.5 to about 6 consists essentially of hydrogen peroxide in a concentration of from about 0.05 to about 8 w/w % of the total solution, at least one anionic surfactant in a concentration of from about 0.02 to about 8 w/w % of the total solution, and at least one additional ingredient chosen from benzyl alcohol, an alcohol comprising one to six carbon atoms, and mixtures thereof, in a concentration of from about 0.1 to about 10 w/w % of the total solution.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: April 7, 2015
    Assignee: Virox Technologies Inc.
    Inventors: Jose A. Ramirez, Navid Omidbakhsh
  • Patent number: 8987244
    Abstract: Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) drug induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the h
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: March 24, 2015
    Assignee: PhilERA New Zealand Limited
    Inventors: Garth J. S. Cooper, John R. Baker
  • Patent number: 8933270
    Abstract: The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: January 13, 2015
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Charles N. Serhan, Bruce D. Levy
  • Publication number: 20150004241
    Abstract: The present invention discloses a method of preparing a solid form of acetic acid. The method at least includes the steps of combining a solid acid and a metal acetate with a solvent to form a slurry. After a predetermined period of time, a solid form of acetic acid is recovered. The present invention also includes a solid product of acetic acid produced by the above-mentioned method. There is also disclosed a formulation including the solid product of acetic acid according to the present invention. Further, there is disclosed a cleaning system including the formulation according to the present invention.
    Type: Application
    Filed: September 16, 2014
    Publication date: January 1, 2015
    Applicant: ChemLink Laboratories, LLC
    Inventors: Ryan Giffin MOORE, Lucas John Smith
  • Patent number: 8921425
    Abstract: The present disclosure relates to compositions comprising formic acid as an active ingredient and a softening agent or emollient for use in the treatment of fungal infections of the skin and/or nail(s) of mammals, as well as methods for treatment utilizing such compositions.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: December 30, 2014
    Assignee: Abbell AB
    Inventor: Astrid Agholme
  • Patent number: 8916595
    Abstract: The present invention provides a composition having an excellent controlling activity on plant disease. The composition comprising the compound represented by the formula (1) and one or more carbamate fungicidal compound selected from the group (A) shows an excellent controlling activity on a plant disease. group (A): a group consisting of benthiavalicarb, iprovalicarb, propamocarb, and metam.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: December 23, 2014
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: So Kiguchi, Soichi Tanaka, Mayuko Ozawa, Atsushi Iwata
  • Patent number: 8912124
    Abstract: The invention relates to derivatives of (1-cyanocyclopropyl)phenylphosphinic acid of the formula (I) and to salts thereof, of the formula (II), for enhancing stress tolerance in plants to abiotic stress, preferably to drought stress, especially for enhancing plant growth and/or for increasing plant yield.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: December 16, 2014
    Assignee: Bayer Cropscience AG
    Inventors: Lothar Willms, Hans-Joachim Zeiβ, Marco Busch, Christopher Hugh Rosinger, Ines Heinemann, Isolde Häuser-Hahn, Martin Jeffrey Hills, Pascal Von Koskull-Döring
  • Publication number: 20140350113
    Abstract: Described herein are small-molecule mimics of CD4, which both enter the Phe43 cavity and target Asp368 of gp120, the HIV-1 envelope protein. Also described herein are methods of using these compounds to inhibit the transmission or progression of HIV infection. These compounds exhibit antiviral potency greater than that of a known antiviral, NBD-556, with 100% breadth against clade B and C viruses. Importantly, the compounds do not activate HIV infection of CD4-negative, CCR5-positive cells, in contrast to NBD-556.
    Type: Application
    Filed: December 14, 2012
    Publication date: November 27, 2014
    Inventors: Joseph Sodroski, Judith M. LaLonde, Amos B. Smith, III, Peter D. Kwong, Young Do Kwon, David M. Jones, Alexander W. Sun, Joel R. Courter, Takahiro Soeta, Toyoharu Kobayashi, Amy M. Princiotto, Xueling Wu, John R. Mascola, Ame Schon, Emesto Freire, Navid Madani, Matthew Le-Khac, Wayne A. Hendrickson
  • Publication number: 20140309273
    Abstract: Provided are new fatty acid derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, e.g., as agents for the treatment of obesity and related disorders, and for improving cognition.
    Type: Application
    Filed: June 25, 2014
    Publication date: October 16, 2014
    Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., AL-QUDS UNIVERSITY
    Inventors: Jehoshua KATZHENDLER, Meir SAIDIAN, Yousef NAJAJREH, Raphael MEVORACH, Elliot BERRY, Yosefa AVRAHAM
  • Patent number: 8859615
    Abstract: The present invention provides compounds of Formula (I), compositions comprising an effective amount of a compound of Formula (I), optionally with chemotherapeutic drugs such as a tubulin-binding drug, and methods of their use for reducing the toxicity of cytotoxic agents, treating or preventing cancer or a neuropathic disorder, inducing a chemoprotective phase II enzyme, DNA, or protein synthesis, enhancing the immune system, treating inflammation, improving and enhancing general health or well-being, and methods for making compounds of Formula (I).
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: October 14, 2014
    Inventors: Samuel J. Danishefsky, Ting-Chao Chou, Xiaoguang Lei, Heedong Yun, Fay Ng, John Hartung, Dalibor Sames
  • Publication number: 20140301998
    Abstract: Disclosed is a cosmetic or dermatological formulation comprising a) at least one polyol in a concentration of from 0.1 to 20% by weight, based on the total weight of the formulation, and b) at least one diol selected from 2-methyl-1,3-propanediol, pentanediol, and hexanediol, in a concentration of from 0.1 to 25% by weight, based on the total weight of the formulation.
    Type: Application
    Filed: June 2, 2014
    Publication date: October 9, 2014
    Applicant: BEIERSDORF AG
    Inventors: Rainer KROPKE, Jens NIELSEN, Kathrin WOLTER
  • Publication number: 20140286922
    Abstract: A method of measuring the effect of an active agent or a stressor on the baseline metabolic indicators of one or more hair follicles, the method including (a) obtaining one or more hair follicles; (b) placing the one or more hair follicles in a vessel, wherein the one or more hair follicles are positioned under one or more sensors; (c) using the one or more sensors to measure the one or more hair follicles' baseline metabolic indicators for both glycolysis and oxidative phosphorylation; (d) exposing the one or more hair follicles to an active agent or a stressor; and (e) using the one or more sensors to measure the one or more hair follicles' respondent metabolic indicators for both glycolysis and oxidative phosphorylation.
    Type: Application
    Filed: March 19, 2014
    Publication date: September 25, 2014
    Applicant: The Procter & Gamble Company
    Inventors: Ben Charlton HULETTE, Thomas Larry DAWSON, JR.
  • Patent number: 8835500
    Abstract: Therapeutic formulations and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Therapeutic formulations and methods for preventing or treating amyloidosis and/or amyloid-related disease are also described.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: September 16, 2014
    Assignee: BHI Limited Partership
    Inventors: Julie Laurin, Denis Garceau
  • Patent number: 8815936
    Abstract: Described is a composition for preventing or treating an oxidative stress related disease or condition in a subject. The disease or condition is characterized by the presence of excess oxidative compounds in the subject, and the composition includes a synergistic combination of therapeutically effective amounts of resveratrol to promote NAD+ synthesis in the subject; a chelating agent to reduce production of additional oxidative compounds in the subject; and an antioxidant to minimize the oxidative activity in the subject.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: August 26, 2014
    Assignee: Nad Life Pty Ltd
    Inventors: Ross Stewart Grant, Nady Braidy, Gilles Guillemin, George Smythe
  • Patent number: 8809311
    Abstract: A process for improving the health of a subject, the process comprising orally administering a composition comprising hydroxytyrosol to the subject to provide the subject with a daily dose of about 0.1 to about 750 ?g hydroxytyrosol per kg of body weight, and a dietary supplement in dosage unit form for oral administration, the dosage unit form comprising a composition containing about 1 microgram to about 50 milligrams hydroxytyrosol or an ester or salt thereof.
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: August 19, 2014
    Inventor: Darlene McCord
  • Patent number: 8808755
    Abstract: A skin disinfectant in ready-to-use concentrated liquid or dry powdered form. Ready-to-use liquid forms have a pH of from about 2 to about 6 and include: (a) hydrogen peroxide in a concentration of from about 0.01 to about 4% w/w of the solution; (b) at least one surfactant chosen from imidazoline derivatives, alkyl betaines, alkyl amidopropyl betaine amides, alkyl amidopropyl betaines, alkylsulfo betaines, amine oxides and derivatives thereof in a concentration of from about 0.01 to about 15% w/w of the solution; (c) at least one hydrogen peroxide stabilizer in a concentration of from about 0.01 to about 4% w/w of the solution; (d) at least one member chosen from cyclic carboxylic acids and salts thereof in a concentration of from about 0.01 to about 4% w/w of the solution; and (e) at least one skin conditioning agent in a concentration of from about 0.01 to about 10% w/w of the solution.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: August 19, 2014
    Assignee: Virox Technologies Inc.
    Inventor: Navid Omidbakhsh
  • Patent number: 8754121
    Abstract: Methods for treating melanoma in a subject in need thereof are disclosed. The method comprises administering to the subject a composition comprising a therapeutically effective amount of deoxyelephantopin or an analogue thereof; and a pharmaceutically acceptable carrier. Methods of inhibiting proliferation, migration and/or metastasis of melanoma cells in a subject in need thereof are also disclosed. Also disclosed are methods for reducing side effects of an anti-cancer agent in a subject in need thereof.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: June 17, 2014
    Assignee: Academia Sinica
    Inventors: Lie-Fen Shyur, Wen-Wan Chao, Ya-Wen Cheng
  • Publication number: 20140140948
    Abstract: The present invention relates to a method of pre-rinsing laundry and treating other surfaces employing a composition that can kill bedbug eggs. The composition includes an anionic compound and is at pH just above neutral, e.g., about 7 to about 9.
    Type: Application
    Filed: November 20, 2012
    Publication date: May 22, 2014
    Applicant: Ecolab USA Inc.
    Inventors: Kim R. Smith, Erik Olson, Yvonne Killeen, Victor Man, Joelle Olson, Erin Loosbrock
  • Publication number: 20140107027
    Abstract: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.
    Type: Application
    Filed: December 18, 2013
    Publication date: April 17, 2014
    Applicant: BHI LIMITED PARTNERSHIP
    Inventors: Xianqi Kong, David Migneault, Isabelle Valade, Xinfu Wu, Francine Gervais
  • Publication number: 20140073694
    Abstract: The present invention relates to the use of cystamine analogues for the treatment of Parkinson's disease. The present invention also relates to the use of composition comprising cystamine analogues and cysteine. The present invention relates to a method for modifying the progression of Parkinson's disease comprising administering a therapeutically effective amount of at least one cystamine analogue or a pharmaceutically acceptable salt of a cystamine analogue to a patient in need thereof.
    Type: Application
    Filed: February 23, 2012
    Publication date: March 13, 2014
    Applicant: UNIVERSITE LAVAL
    Inventors: Francesca Cicchetti, Claude Rouillard, Frederic Calon
  • Patent number: 8637085
    Abstract: An aqueous disinfecting solution having a pH from about 0.5 to about 6 and consisting essentially of hydrogen peroxide in a concentration from about 0.05 to about 8 w/w % of the total solution; at least one anionic surfactant in a concentration from about 0.02 to about 8 w/w % of the total solution, selected from sulfonated C12 to C22 carboxylic acids and alkali metal, ammonium, calcium and magnesium salts thereof; naphthalene sulfonic acids and alkali metal, ammonium, calcium and magnesium salts thereof; C8 to C22 alkyl sulfonic acids and alkali metal, ammonium, calcium and magnesium salts thereof; and alkyl or alkenyl esters or diesters of sulfosuccinic acids in which the alkyl or alkenyl groups independently contain from six to eighteen carbon atoms and alkali metal, ammonium, calcium and magnesium salts thereof; and benzyl alcohol in a concentration from about 0.1 to about 10 w/w % of the solution.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: January 28, 2014
    Assignee: Virox Technologies Inc.
    Inventors: Jose A. Ramirez, Navid Omidbakhsh
  • Publication number: 20130302389
    Abstract: The present invention relates to a cosmetic composition, which comprises a combination of at least two osmolytes chosen from the group comprising taurine or a derivative thereof, inositol, betaine and trehalose. This composition is intended for restoring, maintaining or reinforcing the moisturization of the skin and/or for protecting it against different types of stress and/or for preventing or retarding the appearance of the signs of aging of the skin, or for attenuating the effects thereof, or alternatively for promoting cell or tissue longevity.
    Type: Application
    Filed: July 17, 2013
    Publication date: November 14, 2013
    Inventors: Marc Dumas, Valerie Krzuch, Delphine Pelle de Queral, Catherine Heusele
  • Publication number: 20130296434
    Abstract: Methods, formulations, and compositions for the treatment of amyloidosis are described.
    Type: Application
    Filed: May 23, 2013
    Publication date: November 7, 2013
    Inventors: Denis Garceau, Wendy Hauck, Richard Briand
  • Patent number: 8568759
    Abstract: The present invention provides an environmentally compatible, pesticidal composition and method for the control of insect pests. The composition includes two components. The first component is a chelating agent, a metal complex of a chelating agent, and mixtures thereof, and the second component is preferably a carrier material.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: October 29, 2013
    Assignee: W. Neudorff GmbH KG
    Inventor: Diana L. Parker
  • Patent number: 8563538
    Abstract: Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: October 22, 2013
    Assignee: Philera New Zealand Limited
    Inventors: Garth J. S. Cooper, John R. Baker
  • Publication number: 20130251858
    Abstract: The invention relates to acidified cocoa nibs, wherein the nibs comprise at least 20 mg/g of polyphenols, preferably more than 30 mg/g of polyphenols, most preferably from 40 to 60 mg/g of polyphenols, cocoa refiner or expeller flakes, liquor, cakes, and cocoa powder obtainable from the nibs and a process for producing cocoa-derived material, comprising the steps of: (i) treating cocoa nibs obtained from beans or seeds which have a higher polyphenol content than fermented cocoa beans with an acid; and (ii) optionally drying the nibs.
    Type: Application
    Filed: May 20, 2013
    Publication date: September 26, 2013
    Applicant: Barry Callebaut AG
    Inventors: Arnaud Dumarche, Philippe Troplin, Herwig Bernaert, Paul Lechevalier, Herve Beerens, Alex Landuyt
  • Publication number: 20130165521
    Abstract: The present disclosure relates to compositions comprising formic acid as an active ingredient and a softening agent or emollient for use in the treatment of fungal infections of the skin and/or nail(s) of mammals, as well as methods for treatment utilizing such compositions.
    Type: Application
    Filed: September 12, 2011
    Publication date: June 27, 2013
    Applicant: ABBELL AB
    Inventor: Astrid Agholme
  • Publication number: 20130158070
    Abstract: Novel chemical conjugates derived from unsaturated fatty acids and therapeutically active agents, are disclosed. The chemical conjugates are designed and characterized as COX-2 and/or 5-LOX inhibitors and are useful in the treatment of inflammatory diseases and disorders such as Alzheimer's disease, Parkinson's disease, asthma, osteoarthritis, rheumatoid arthritis, pain, primary dysmenorrhea, Crohn's disease and ulcerative colitis.
    Type: Application
    Filed: September 6, 2011
    Publication date: June 20, 2013
    Inventor: Taher Nassar
  • Publication number: 20130143867
    Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.
    Type: Application
    Filed: January 18, 2013
    Publication date: June 6, 2013
    Applicant: SYCHRONEURON INC.
    Inventor: SYCHRONEURON INC.
  • Publication number: 20130137772
    Abstract: A salt of a polyamine having the formula: with a pharmaceutically acceptable organic or inorganic acid, wherein at least one of the bridging groups ALK1, ALK2 and ALK3 contains at least one —CH(OH)-group which is not alpha- to any of the nitrogen atoms.
    Type: Application
    Filed: November 29, 2011
    Publication date: May 30, 2013
    Inventor: Raymond J. Bergeron
  • Patent number: 8445535
    Abstract: Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of triglycerides or fatty acids with chain lengths between 5 and 12, to said patient at a level to produce an improvement in cognitive ability.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: May 21, 2013
    Assignee: Accera, Inc.
    Inventor: Samuel T Henderson
  • Publication number: 20130123358
    Abstract: Sodium butyrate was chronically administrated through diet supplementation at 5% w/w in a high fat diet. Supplementation of butyrate prevented development of insulin resistance and obesity in C57BL/6J mice on a high fat diet, and in mice fed on a regular diet of tributyrin. Fasting blood glucose, insulin, and insulin tolerance were all reserved in the butyrate-treated mice. The body fat content was maintained at 10% without a reduction in food intake. Adaptive thermogenesis and fatty acid oxidation were enhanced. An increase in mitochondria function and biogenesis was observed in the skeletal muscle and brown fat, and Type 1 muscle fiber was enriched in the skeletal muscle. In genetically obese mice, supplementation of butyrate led to an increase in insulin sensitivity and reduction in adiposity. Dietary supplementation of butyrate can prevent and treat diet-induced insulin resistance.
    Type: Application
    Filed: December 20, 2012
    Publication date: May 16, 2013
    Inventors: Jianping Ye, Zhanguo Gao
  • Publication number: 20130121985
    Abstract: Methods for treating male sub-fertility by administering a pharmaceutical composition to a subject in need thereof are provided. The pharmaceutical compositions include an agent that causes a reduction in an effect of extracellular DNA on sperm cells. The agent may be, for example, an enzyme that degrades DNA such as DNase, a substance that blocks the interaction between cell free DNA and sperm cell surface receptors, a substance that binds to DNA, a substance that inhibits endogenous sperm cell DNase, a substance that inhibits a member of a signal transduction pathway mediated by DNA binding to sperm cell surface receptors, or an agent that stimulates production of an endogenous substance that causes a reduction in an antifertility effect of cell free DNA on sperm cells.
    Type: Application
    Filed: December 20, 2012
    Publication date: May 16, 2013
    Inventors: Benjamin BARTOOV, Ronen YEHUDA, Melamed DOBROSLAV
  • Patent number: 8426468
    Abstract: Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of triglycerides or fatty acids with chain lengths between 5 and 12, to said patient at a level to produce an improvement in cognitive ability.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: April 23, 2013
    Assignee: Accera, Inc.
    Inventor: Samuel T. Henderson
  • Publication number: 20130085182
    Abstract: The present invention refers to 2-mercaptoethane sulfonate or pharmaceutically acceptable salts thereof and to pharmaceutical compositions comprising it for epidural use in the treatment of lumbar pain.
    Type: Application
    Filed: October 13, 2011
    Publication date: April 4, 2013
    Applicant: UNIVERSITA' CAMPUS BIO-MEDICO DI ROMA
    Inventors: Massimiliano Carassiti, Felice Eugenio Agrò, Vincenzo Denaro, Alberto Corrado Di Martino
  • Patent number: 8409630
    Abstract: The process involves (a) continuously forming bromine chloride from separate feed streams of bromine and chlorine by maintaining said streams under automatic feed rate control whereby the streams are continuously proportioned to come together in equimolar amounts to form bromine chloride; (b) continuously forming an aqueous product having an active bromine content of at least 100,000 ppm (wt/wt), a pH of at least 7, and an atom ratio of nitrogen to active bromine greater than 0.93:1 by continuously feeding into mixing apparatus separate feed streams of (1) bromine chloride formed in (a), and (2) an aqueous solution of alkali metal salt of sulfamic acid, under automatic feed rate control whereby the feed streams are continuously proportioned to come together in amounts that produce an aqueous product having an active bromine content of at least 100,000 ppm (wt/wt), a pH of at least 7, and an atom ratio of nitrogen to active bromine from (1) and (2) greater than 0.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: April 2, 2013
    Assignee: Albermarle Corporation
    Inventors: Robert M. Moore, Jr., Christopher J. Nalepa
  • Patent number: 8383679
    Abstract: The present invention relates to a novel crystal form of calcium 3-acetylaminopropane-1-sulfonate, to a process for the preparation thereof, and to the use thereof in medicaments.
    Type: Grant
    Filed: August 25, 2009
    Date of Patent: February 26, 2013
    Assignee: Merck Patent Gesellschaft mit beschränkter Haftung
    Inventors: Antje Ernst, Clemens Kuehn, Matthias Bartels, Christoph Saal, Nathalie Bosc
  • Patent number: 8372886
    Abstract: Disclosed herein are methods, compounds and compositions for preventing or treating a renal disorder or chronic kidney diseases, including nephropathies such as diabetic nephropathy. The invention generally includes administering to a subject 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof, e.g., 1,3-propanedisulfonic acid sodium salt. The invention also relates to methods, compounds and compositions for the prevention and/or treatment of for preventing or treating a renal disorder complication. The invention further relates to methods, compounds and compositions for the prevention and/or treatment of dyslipidemia, and more particularly for reducing levels of harmful serum lipid levels, especially cholesterol and triglycerides in diabetic patients.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: February 12, 2013
    Assignee: Kiacta Sarl
    Inventors: Wendy Hauck, Pavel Hamet
  • Publication number: 20130004589
    Abstract: Compositions and methods for treating and/or preventing conditions such as diaper rash and atopic dermatitis are disclosed. The compositions and methods are particularly useful in the treatment and prevention of diaper rash and diaper dermatitis caused by the prolonged contact of human skin with body waste. The methods employ the topical application of a trypsin-inhibiting agent to the area in need of such treatment, or the area where prevention is desired. The trypsin-inhibiting agent is preferably a divalent cation/anion pair.
    Type: Application
    Filed: June 28, 2011
    Publication date: January 3, 2013
    Inventors: Connie B. Lin, Euen Thomas Graham Ekman Gunn, Ya-Ping Hu, Neema Kulkarni, Mary Catherine Mack